Table 4.
Urine NGAL (ng/ml) | Baseline | 3 hr | 6 hr | 12 hr | 18 hr | 24 hr |
---|---|---|---|---|---|---|
All patients | ||||||
Placebo group (n = 50) |
61 ± 42 |
164 ± 144 |
174 ± 134 |
164 ± 113 |
137 ± 95 |
122 ± 87 |
rHuEPO group (n = 50) |
55 ± 51 |
105 ± 76* |
109 ± 64# |
114 ± 67# |
101 ± 62* |
93 ± 56 |
Patients with acute kidney injury | ||||||
Placebo group (n = 19) |
65 ± 23 |
281 ± 151 |
296 ± 140 |
271 ± 81 |
207 ± 107 |
173 ± 105 |
rHuEPO group (n = 7) |
62 ± 28 |
176 ± 41* |
167 ± 40# |
164 ± 57# |
128 ± 55* |
101 ± 52* |
Patients without acute kidney injury | ||||||
Placebo group (n = 31) |
58 ± 50 |
99 ± 89 |
106 ± 66 |
104 ± 79 |
98 ± 60 |
94 ± 61 |
rHuEPO group (n = 43) | 54 ± 54 | 93 ± 75 | 100 ± 64 | 106 ± 66 | 97 ± 64 | 92 ± 58 |
Data are expressed as mean ± S.D.
Significant differences by Bonferroni post-hoc test of ANOVA.
*p < 0.05, #p < 0.01 compared between placebo and rHuEPO group.